Collectively, the findings indicate that UC-MSCs-EVs attenuate psoriasis-like inflammation through convergent inhibition of DC-derived IL-23 and keratinocyte STAT3 signaling, supporting their development as a cell-free immunomodulatory therapy for chronic inflammatory skin disease. The gene discussed is STAT3; the disease is psoriasis.